| FDA panel gives nod to Merck's Vytorin - Cardiovascular Business |
|
|
Cardiovascular Business 2 to recommend Merck's Vytorin (combination ezetimibe/simvastatin) for use in patients with pre-dialysis chronic kidney disease. However, when it came to whether or not the approval should include patients with end-stage renal disease receiving |